Utilizing Mosunetuzumab in Follicular Lymphoma Care

Matthew Matasar, MD, chief of the division of blood disorders at the Rutgers Cancer Institute and professor at the Rutgers Robert Wood Johnson Medical School, highlights the use of mosunetuzumab-axgb (Lunsumio) for the treatment of patients with follicular lymphoma.

At the 2023 American Society of Hematology (ASH) Annual Meeting, Matasar presented updated findings on mosunetuzumab, demonstrating encouraging results in terms of both progression-free survival (PFS) and duration of response. He noted a median PFS of approximately 2 years for heavily pretreated patients and a median duration of response of 3 years, highlighting the importance of these data.

Matasar also emphasized that these findings provide further support for the broader use of mosunetuzumab in various care settings. Importantly, no new safety signals were identified during the follow-up period. This indicates the appropriateness of this treatment for community-based settings. Further, these results reinforce the potential of mosunetuzumab as a valuable therapeutic option for patients with relapsed follicular lymphoma.

Transcription:

0:09 | Mosunetuzumab is the first bispecific approved in the treatment of relapse follicular lymphoma as a monotherapy. At ASH, we presented our updated findings as we continue to follow these patients to learn more about the durability of this therapy. The results presented here were very encouraging. We see prolongation in both the progression-free survival, PFS, as well as the duration of response with a median PFS for these heavily pretreated patients was just about 2 years. The median duration of response was 3 years. This is very important data.

0:42 | This is further ammunition to support our broader deployment of mosunetuzumab in a number of care settings. In addition to the updates on activity, we also importantly found no new safety signals as we follow the cord over time, again, reaffirming that this is treatment that is appropriate for community-based settings.